Scotland says yes to Merck & Co's Simponi and Astellas' Dificlir
This article was originally published in Scrip
Executive Summary
The Scottish medicines Consortium has accepted for use on Scotland's NHS Merck & Co's anti-TNF Simponi (golimumab) for psoriatic arthritis. The consortium also gave a restricted green light to Astellas' Dificlir (fidaxomicin) for adults with Clostridium difficile infections.